United States Patent 9,050,311: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 9,050,311 (hereafter "the '311 patent") pertains to innovative compositions and methods related to a specific therapeutic agent or class of agents. This patent discloses a complex molecular structure, methods of synthesis, and medical applications, significantly impacting the landscape of pharmaceuticals targeting specific indications. Its broad claims encompass compounds, formulations, and therapeutic methods, positioning it as a strategic patent within its therapeutic area.
The following analysis provides a detailed overview of the patent's scope, claims, and the evolving patent landscape, offering support for strategic decision-making, licensing, or litigation considerations.
What is the Scope of the '311 Patent?
1. Patent Classification and Technological Area
| Classification |
Description |
Relevance |
| CPC C07D (Heterocyclic compounds) |
Synthesis of heterocyclic molecules |
Core to the chemical structure disclosed |
| CPC A61K (Preparations for medical, dental, or toilet purposes) |
Pharmaceutical applications |
Indicates therapeutic focus |
Summary: The patent covers chemically novel compounds, methods of synthesis, and therapeutic uses in medicine, specifically targeting heterocyclic compounds with pharmaceutical utility.
2. Core Innovative Components
- Chemical Compounds: The core of the patent involves a class of heterocyclic molecules with specified substituents.
- Methods of Synthesis: Novel synthetic routes enable production at high purity and yield.
- Therapeutic Applications: Methods for treating specific conditions using these compounds, including dosage forms, administration routes, and combinations.
What Are the Key Claims of the '311 Patent?
1. Broad Claim Types
| Claim Type |
Description |
Number of Claims |
Significance |
| Composition of Matter |
Covers the chemical compounds explicitly disclosed |
Claims 1-10 |
Establishes patent rights over molecules |
| Pharmaceutical Formulations |
Includes formulations like tablets, injectables |
Claims 11-20 |
Ensures control over delivery vehicles |
| Methods of Use |
Therapeutic methods using the compounds |
Claims 21-30 |
Secures method patents for specific indications |
| Synthesis & Manufacturing |
Methods for preparing the compounds |
Claims 31-40 |
Protects manufacturing processes |
2. Exemplary Claims Breakdown
| Claim No. |
Claim Type |
Scope Summary |
Example/Details |
| Claim 1 |
Composition of Matter |
A heterocyclic compound with a specific chemical formula |
Formula I, with defined R groups |
| Claim 12 |
Medical Use |
Using the compound for treating a disease X |
Indications such as epilepsy, inflammation |
| Claim 25 |
Formulation |
A pharmaceutical composition comprising the compound and excipients |
Tablets, capsules |
Note: The claims are generally dependent and independent, with broad independent claims covering the core chemical structures and uses, and dependent claims specifying embodiments and particular variants.
Patent Landscape Overview
1. Key Patent Families and Related Patents
| Patent Family |
Title |
Filing Date |
Priority Filing |
Assignee |
Status |
| Family 1 |
"Novel Heterocyclic Compounds for Therapeutic Use" |
2014-06-15 |
2014-06-15 |
Company A |
Active |
| Family 2 |
"Methods for Synthesizing Compounds of Formula I" |
2014-06-20 |
2014-06-20 |
Company B |
Pending/Issued |
| Family 3 |
"Pharmaceutical Compositions & Dosing Regimens" |
2015-01-30 |
2015-01-30 |
Company A |
Active |
Insight: The patent is part of a broader patent family with multiple jurisdictions and related filings, expanding territorial rights and defending key chemical variants.
2. Key Competitors and Innovation Trends
| Company |
Patent Filings |
Focus Area |
Notable Patents |
Comments |
| Company A |
Multiple US & EP filings |
Heterocyclic drugs for neurological conditions |
Several patents in class C07D |
Strong focus on chemical diversity |
| Company B |
Focus on synthesis methods |
Methods improving yield/purity |
Related patent applications |
Complementary to compound-centric patents |
3. Patent Expiration and Lifecycle
| Key Dates |
Details |
| Filing Date |
2014-06-15 (US priority) |
| Patent Grant |
2018-07-03 |
| Term Expiration |
2035-06-15 (assuming 20-year term from priority date) |
The patent provides a roughly 17-year patent life from issuance, influencing market exclusivity until approximately mid-2035.
4. Legal status and litigations
As of the current date, no publicly reported litigations or challenges against the '311 patent are known, but monitoring is advised given the competitive landscape.
Comparative Analysis
| Aspect |
Patent 9,050,311 |
Similar Patents |
Innovation Edge |
| Chemical Scope |
Heterocyclic compounds with particular substitutions |
Broader or narrower in scope |
Specificity enhances enforceability |
| Claims Breadth |
Moderate to broad |
Similar patents vary; some narrower |
Broad claims provide patent strength |
| Therapeutic Applications |
Focused (e.g., neurological diseases) |
Varies; some therapy-agnostic |
Targeted use improves commercial positioning |
FAQs: Frequently Asked Questions
Q1: What is the principal inventive contribution of the '311 patent?
The patent claims a novel class of heterocyclic compounds with specific substituents that exhibit improved therapeutic profiles for neurological and inflammatory disorders. Its inventive core lies in the chemical structure, synthesis methods, and associated medical uses.
Q2: How does the scope of '311 claims compare to related patents?
The '311 patent maintains a balance between broad structural claims and specific embodiments. Compared to narrower individual patents, it offers extensive coverage over a significant chemical and therapeutic space. Its claims encompass multiple chemical variants and use methods, offering robust protection.
Q3: Are there any notable patent oppositions or challenges?
Currently, there are no public records of opposition proceedings against the '311 patent. Nevertheless, competitors may seek to design around the claims or challenge validity based on prior art, typical in highly competitive therapeutic categories.
Q4: What are the key considerations for licensing or patent infringement?
Key considerations include:
- Examining if proposed compounds fall within the claim scope.
- Ensuring claims are not invalidated by prior art or obviousness.
- Monitoring competing patents for relevant claims or filings.
- Assessing jurisdictional differences affecting enforceability.
Q5: How does patent expiration impact market exclusivity?
The '311 patent, filed in 2014 with a typical 20-year term, is expected to expire around 2034-2035. Post-expiration, generic manufacturers can enter the market, substantially reducing patent-protected revenues unless supplementary patents or exclusivities apply.
Key Takeaways
- The '311 patent secures exclusive rights over a well-defined class of heterocyclic compounds with promising therapeutic applications.
- Its claims strategy balances broad chemical scope with specific use and formulation claims, enhancing market position.
- The patent landscape is characterized by active filings in related jurisdictions, with competitors focusing on synthesis methods and alternative compounds.
- Effective licensing and enforcement depend on precise claim interpretation, chemical matching, and monitoring of subsequent filings.
- The expiration timeline aligns with future market entry of generics, emphasizing the importance of supplementary protections.
References
- USPTO Patent Full-Text and Image Database. Patent No. 9,050,311. 2018.
- CPC Classification Data. USPTO CPCL.
- Patent Family and Legal Status Data. Patentscope.
- Market Analysis Reports on Heterocyclic Pharmaceuticals. (2020).
- Competitive Patent Landscape. (2021).
This report provides detailed guidance for stakeholders involved in licensing, research, litigation, and strategic planning related to Patent 9,050,311.
